Gamma Scintigraphy of the Biodistribution of ¹²³I-Labelled N-(2-Hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates in Mice with Transplanted Melanoma and Mammary Carcinoma

References

• Andrew S. M., Perkins A. C., Pimm M. V., Baldwin R. W. A comparison of iodine and indium labelled anti-CEA intact antibody, F(ab')2 and Fab fragments by tumour imaging. Eur. J. Nucl. Med. (1988); 13: 598–604
   PubMedGoogle Scholar
• Cassidy J., Duncan R., Morrison G. J., Strohalm J., Plocova D., Kopecek J., Kaye S. B. Activity of N-(2-hydroxypro-pyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. (1989); 38: 875–879
   PubMed Web of Science ®Google Scholar
• Duncan R., Rejmanova P., Kopecek J., Lloyd J. B. Pinocytic uptake and intracellular degradation of N-(2-hy-droxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta (1981); 678: 143–150
   PubMed Web of Science ®Google Scholar
• Duncan R., Hume I. C., Kopeckova P., Ulbrich K., Strohalm J., Kopecek J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers, 3. Evaluation of adriamycin conjugates against mouse leukaemia L121. in vivo, J. Controlled Rel. (1989); 10: 51–63
   Web of Science ®Google Scholar
• Duncan R. Polymer-drug conjugates: potential for improved chemotherapy. Anti-Cancer Drugs (1992); 3: 175–210
   PubMed Web of Science ®Google Scholar
• Duncan R., Vasey P., Kaye S. B., Cassidy J. Development of PK1 an HPMA copolymer doxorubicin conjugate, the CRC experience. Proceedings of the EORTC Early Drug Development Meeting, CorfuGreece, June, 21–241995, 60–61
   Google Scholar
• Demignot S., Pimm M. V., Thorpe S. R., Baldwin R. W. Differences between the catabolism and rumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumor xenografts revealed by the use of a residualising radiolabel (Dilactitol-125I-Tyramine) and autoradiography. Cancer Immunol, lmmunother. (1991); 33: 359–366
   PubMed Web of Science ®Google Scholar
• Kopecek J., Rejmanova P., Chytry V. Polymers containing enzymatically degradable bonds. 1. Chymptrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chetn. (1981); 182: 799–809
   Web of Science ®Google Scholar
• Maeda H., Seymour L. W., Miyamoto Y. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. (1992); 3: 351–362
   PubMed Web of Science ®Google Scholar
• O'Hare K. B., Duncan R., Strohalm J., Kopeckova P., Kopecek J., Ulbrich K. Macromolecular prodrugs containing doxorubicin and melanocyte stimulating hormone in vitro and in vivo evaluation against murine melanoma. J. Drug Targeting (1993); 1: 217–230
   PubMed Web of Science ®Google Scholar
• Pimm M. V., Perkins A. C., Hudecz F. Scintigraphic evaluation of the pharmacokinetics of a soluble polymeric drug carrier. Eur. J. Nucl. Med. (1992); 19: 449–452
   PubMedGoogle Scholar
• Pimm M. V., Perkins A. C., Duncan R., Ulbrich K. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: Visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Targeting (1993); 1: 125–131
   PubMed Web of Science ®Google Scholar
• Pimm M. V., Perkins A. C., Gribben S. J., Hudecz F. Scintigraphic determination of the biodistribution of an In-111 labelled poly(L-lysine) backbone branched polypeptide drug carrier in tumour-bearing mice. J. Nucl. Biol. Med. (1994); 38(suppl. 1 to no. 4)104–108
   PubMedGoogle Scholar
• Rejmanova P., Kopecek J., Pohl J., Baudys M., Kostka V. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. (1983); 184: 2009–2020
   Web of Science ®Google Scholar
• Rihova B., Ulbrich K., Strohalm J., Vetvicka V, Bilej M., Duncan R., Kopecek J. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymer containing adriamycin. Immunogenicity, effect on haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials (1989); 10: 335–342
   PubMed Web of Science ®Google Scholar
• Richardson A. P., Mountford P. J., Baird A. C., Heyderman E., Richardson T. C., Coakley A. J. An improved Iodogen method of labelling antibodies with 123I. Nucl. Med. Commun. (1986); 7: 355–362
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Ulbrich K., Strohalm J., Kopecek Duncan J. R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol (1990); 39: 1125–1131
   PubMed Web of Science ®Google Scholar
• Seymour L. W. Passive tumor targeting of soluble macro-molecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. (1992); 9: 135–187
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Ulbrich K., Styger P. S., Brereton M., Subr V., Strohalm J., Duncan R. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. British J. Cancer (1994); 70: 636–641
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Miyamoto Y., Brereton M., Styger P. S., Maeda H., Ulbrich K., Duncan R. Influence of molecular size on passive tumour-accumulation of soluble macromolecular drug carriers. Eur. J. Cancer (1995); 31: 766–770
   Web of Science ®Google Scholar
• Strobel J. L., Baynes J. W., Thorpe S. R. 125Iglycoconjugate labels for identifying sites of protein catabolism in vivo; Effect of structure and chemistry of coupling to protein on label entrapment in cells after protein degradation. Arch. Biochem. Biophys. (1985); 240: 635–645
   PubMed Web of Science ®Google Scholar
• Yeung T. K., Hopewell J. W., Simmonds R. H., Seymour L. W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotoxicity of doxorubicin administered in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. (1991); 29: 105–111
   PubMed Web of Science ®Google Scholar